SCHEMBL1828629

SCHEMBL1828629

N#Cc1c(O)ccn(CC2CC2)c1=O

nearest known ligand 0.57

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 20/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827879 0.85 GRM2 (0.59) GRM2
SCHEMBL1828571 0.82 GRM2 (0.54) GRM2
SCHEMBL1827372 0.78 GRM2 (0.61) GRM2
SCHEMBL2187620 0.76 GRM2 (0.52) GRM2
SCHEMBL1038095 0.76 GRM2 (0.54) GRM2
SCHEMBL1038947 0.75 GRM2 (0.53) GRM2
SCHEMBL101802 0.73 GRM2 (1.00) GRM2
SCHEMBL13411096 0.73 GRM2 (0.67) GRM2
SCHEMBL171187 0.73 GRM2 (0.54) GRM2
SCHEMBL4131086 0.72 GRM2 (0.42) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067891-B2 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2015-06-30 US disclosed
US-9067891-B2 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2015-06-30 US disclosed
US-9067891-B2 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2015-06-30 US disclosed
US-8906939-B2 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives Janssen Pharmaceuticals, Inc. (US) 2014-12-09 US disclosed
US-8906939-B2 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives Janssen Pharmaceuticals, Inc. (US) 2014-12-09 US disclosed
US-8906939-B2 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives Janssen Pharmaceuticals, Inc. (US) 2014-12-09 US disclosed
US-8796311-B2 2014-08-05 US disclosed
US-8796311-B2 2014-08-05 US disclosed
US-8796311-B2 2014-08-05 US disclosed
US-20130150412-A1 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR ADDEX PHARMA, S.A. (CH) 2013-06-13 US disclosed
US-20100087487-A1 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES Ortho-McNeil Janssen Pharmaceuticals Inc. (US) 2010-04-08 US disclosed
US-20100063092-A1 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-03-11 US disclosed
US-20100063092-A1 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-03-11 US disclosed
US-20100063092-A1 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-03-11 US disclosed
EP-2134701-A1 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
EP-2134690-A1 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
EP-2134708-A1 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
WO-2008107481-A1 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2008-09-12 WO disclosed
WO-2008107480-A1 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2008-09-12 WO disclosed
WO-2008107479-A1 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063092-A1 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES GRM2, GRIK2, GRIN2C GRM2 1/4885
US-20100087487-A1 3-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVES GRM2, GRM3, GRIK2 GRM2 1/4885
US-20130150412-A1 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR GRM2, GRM1, GRM3 GRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.